RPS6KB1 and asthma: There were no statistically significant differences between the treatment groups, indicating that p-PI3K, p-Akt, p-mTOR, and p-p70S6k offer four novel potential targets for the next generation of asthma treatments as alternatives to the current standard of budenoside.